Ecteinamycin Ionophore Disrupts Bacterial Membrane Potential
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial treatments are inadequate for effectively addressing bacterial infections caused by resistant strains such as Clostridium, Staphylococcus, and Enterococcus, particularly methicillin-resistant S. aureus and vancomycin-resistant Enterococcus, due to limitations in ion transport disruption and membrane depolarization mechanisms.
Innovation Solution
The development of ecteinamycin, a compound isolated from Actinomadura, which acts as an ionophore to disrupt ion transport in bacteria, is administered to mammals to treat bacterial infections, potentially combined with other antibacterial agents for synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then treatment of susceptible bacteria is effective, but treatment of resistant strains (MRSA, VRE) fails
Solution Approach 1:
The patent changes the mechanism of action parameter from conventional antibiotic targets (protein synthesis, cell wall synthesis) to ion transport disruption. Ecteinamycin operates through a fundamentally different biochemical parameter (ionophoric activity) that bypasses bacterial resistance mechanisms developed against traditional antibiotics, thereby restoring reliability against resistant strains while expanding adaptability to multiple bacterial species including MRSA and VRE.
Solution Approach 2:
Ecteinamycin functions as a hybrid molecule combining features of ionophores and antibiotics. Its structure enables it to act as an ion transporter while also exhibiting antibacterial properties, creating a composite functional entity that simultaneously disrupts ion gradients and kills bacteria, including resistant strains that have evolved defenses against conventional single-mechanism antibiotics.
2Adaptability or versatility
If ion transport disruption mechanism is used, then activity against resistant strains improves, but understanding of mechanism is limited
Solution Approach 1:
The patent uses membrane potential and ion gradients as intermediary measurable parameters to detect and characterize ecteinamycin's mechanism. By measuring changes in membrane depolarization, ion flux, and membrane potential using established biochemical assays, the difficult-to-detect ionophoric mechanism is translated into measurable signals that confirm ecteinamycin's mode of action against resistant bacteria.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Eteinamycin demonstrates potent antibacterial activity against resistant strains by disrupting ion transport and membrane potential, offering effective treatment options for bacterial infections, including those resistant to conventional antibiotics.
Implementation Method 1
acts as an ionophore to disrupt ion transport in bacteria
Implementation Method 2
disrupting ion transport and membrane potential
Data Source
AI summary
An isolated or synthesized compound of Formula I and salts thereof are provided. A compound isolated from Actinomadura and having a chemical formula of C38H60O12 is also provided. Compositions including the compounds and methods of using the compounds to treat bacterial infections including gram positive infections such as C. difficile are also disclosed.